This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.本申請案揭示根據通式I之化合物：其中所有變數均如本文所述定義，該等化合物抑制Btk。本文揭示之化合物適用於調節Btk之活性及治療與過度Btk活性相關之疾病。該等化合物適用於治療由異常B細胞活化引起之致癌、自體免疫及發炎疾病。亦揭示含有式I化合物及至少一種載劑、稀釋劑或賦形劑之組合物。
